{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:03:30Z","timestamp":1793361810459,"version":"4.5.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.berh.2020.101503","type":"journal-article","created":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T01:07:11Z","timestamp":1586567231000},"page":"101503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"title":["Clinical manifestations and treatment of antisynthetase syndrome"],"prefix":"10.1016","volume":"34","author":[{"given":"Joanna L.","family":"Marco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget F.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.berh.2020.101503_bib1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/BOR.0000000000000555","article-title":"Antisynthetase syndrome pathogenesis: knowledge and uncertainties","volume":"30","author":"Gallay","year":"2018","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2020.101503_bib2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11926-015-0532-1","article-title":"Role of Jo-1 in the immunopathogenesis of the anti-synthetase syndrome","volume":"17","author":"Ascherman","year":"2015","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"10.1016\/j.berh.2020.101503_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.md.0000217525.82287.eb","article-title":"Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies","volume":"85","author":"O'Hanlon","year":"2006","journal-title":"Medicine (Baltim)"},{"issue":"6","key":"10.1016\/j.berh.2020.101503_bib4","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/annrheumdis-2011-200182","article-title":"Interaction of HLA-DRB1\u221703 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study","volume":"71","author":"Chinoy","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2020.101503_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/thx.2006.069237","article-title":"Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset","volume":"63","author":"Tillie-Leblond","year":"2008","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.berh.2020.101503_bib6","first-page":"950","article-title":"Environmental triggers of autoimmunity in anti-synthetase syndrome: the lungs under the spot light","volume":"31","author":"Kawano-Dourado","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2020.101503_bib7","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/art.39059","article-title":"Nested case-control study of selected systemic autoimmune diseases in World Trade Center rescue\/recovery workers","volume":"67","author":"Webber","year":"2015","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"1","key":"10.1016\/j.berh.2020.101503_bib8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/art.41075","article-title":"Proinflammatory histidyl-transfer RNA synthetase-specific CD4+ T cells in the blood and lungs of patients with idiopathic inflammatory myopathies","volume":"72","author":"Galindo-Feria","year":"2020","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"7","key":"10.1016\/j.berh.2020.101503_bib9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.berh.2020.101503_bib10","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"European League against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2020.101503_bib11","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamaneurol.2017.0934","article-title":"Skeletal muscle involvement in antisynthetase syndrome","volume":"74","author":"Noguchi","year":"2017","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.berh.2020.101503_bib12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CPM.0000000000000171","article-title":"The diagnosis and treatment of antisynthetase syndrome","volume":"23","author":"Witt","year":"2016","journal-title":"Clin Pulm Med"},{"issue":"12","key":"10.1016\/j.berh.2020.101503_bib13","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.berh.2020.101503_bib14","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.berh.2020.101503_bib15","first-page":"100","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"37","author":"Solomon","year":"2011","journal-title":"J\u00a0Bras Pneumol Publicacao Soc Bras Pneumol E Tisilogia"},{"issue":"32","key":"10.1016\/j.berh.2020.101503_bib16","doi-asserted-by":"crossref","first-page":"e1144","DOI":"10.1097\/MD.0000000000001144","article-title":"Clinical spectrum time course in anti jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study","volume":"94","author":"Cavagna","year":"2015","journal-title":"Medicine (Baltim)"},{"issue":"1","key":"10.1016\/j.berh.2020.101503_bib17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2020.101503_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11926-012-0249-3","article-title":"Morbidity and mortality in adult polymyositis and dermatomyositis","volume":"14","author":"Marie","year":"2012","journal-title":"Curr Rheumatol Rep"},{"issue":"10","key":"10.1016\/j.berh.2020.101503_bib19","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.rmed.2014.09.003","article-title":"Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type","volume":"108","author":"Johnson","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.berh.2020.101503_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.rmed.2016.07.009","article-title":"Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome","volume":"118","author":"Zamora","year":"2016","journal-title":"Respir Med"},{"issue":"9","key":"10.1016\/j.berh.2020.101503_bib21","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1445-5994.2010.02164.x","article-title":"Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies","volume":"41","author":"Dugar","year":"2011","journal-title":"Intern Med J"},{"issue":"4","key":"10.1016\/j.berh.2020.101503_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060442","article-title":"Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome","volume":"8","author":"Hamaguchi","year":"2013","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.berh.2020.101503_bib23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11926-013-0349-8","article-title":"Clinical heterogeneity and outcomes of antisynthetase syndrome","volume":"15","author":"Hervier","year":"2013","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.berh.2020.101503_bib24","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ejrad.2014.11.026","article-title":"Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings","volume":"84","author":"Debray","year":"2015","journal-title":"Eur J Radiol"},{"issue":"3","key":"10.1016\/j.berh.2020.101503_bib25","first-page":"210","article-title":"Predictive factors for the long-term deterioration of pulmonary function in interstitial lung disease associated with anti-aminoacyl-tRNA synthetase antibodies","volume":"96","author":"Yamakawa","year":"2018","journal-title":"Respir Int Rev Thorac Dis"},{"issue":"8","key":"10.1016\/j.berh.2020.101503_bib26","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ejrad.2016.05.012","article-title":"Antisynthetase syndrome: pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases","volume":"85","author":"Waseda","year":"2016","journal-title":"Eur J Radiol"},{"issue":"6","key":"10.1016\/j.berh.2020.101503_bib27","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3899\/jrheum.151067","article-title":"Pulmonary involvement in the antisynthetase syndrome: a comparative cross-sectional study","volume":"43","author":"Andersson","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2020.101503_bib28","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3899\/jrheum.161480","article-title":"Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies","volume":"44","author":"Shi","year":"2017","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2020.101503_bib29","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.chest.2016.06.019","article-title":"Surgical lung biopsy for interstitial lung diseases","volume":"151","author":"Raj","year":"2017","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.berh.2020.101503_bib30","first-page":"177","article-title":"Interstitial lung disease evaluation: detecting connective tissue disease","volume":"90","author":"Fischer","year":"2015","journal-title":"Respir Int Rev Thorac Dis"},{"issue":"3 Pt 1","key":"10.1016\/j.berh.2020.101503_bib31","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1164\/ajrccm\/151.3_Pt_1.909","article-title":"Interstitial lung disease: a diagnostic approach. Are CT scan and lung biopsy indicated in every patient?","volume":"151","author":"Raghu","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.berh.2020.101503_bib32","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1183\/09031936.00156312","article-title":"Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival","volume":"42","author":"Hervier","year":"2013","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.berh.2020.101503_bib33","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/rheumatology\/kep455","article-title":"Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases","volume":"49","author":"Hervier","year":"2010","journal-title":"Rheumatol Oxf Engl"},{"issue":"4","key":"10.1016\/j.berh.2020.101503_bib34","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s13311-018-00676-2","article-title":"Autoimmune myopathies: updates on evaluation and treatment","volume":"15","author":"McGrath","year":"2018","journal-title":"Neurotherapeutics"},{"issue":"7","key":"10.1016\/j.berh.2020.101503_bib35","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/rheumatology\/kem088","article-title":"The role of MRI in the assessment of polymyositis and dermatomyositis","volume":"46","author":"Tomasov\u00e1 Studynkov\u00e1","year":"2007","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.berh.2020.101503_bib36","author":"Jensflorian"},{"issue":"2","key":"10.1016\/j.berh.2020.101503_bib37","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.berh.2020.101503_bib38","first-page":"44","article-title":"Timing of onset affects arthritis presentation pattern in antisynthetase syndrome","volume":"36","author":"Gonz\u00e1lez-Gay","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2020.101503_bib39","article-title":"Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course","volume":"8","author":"Cavagna","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"9","key":"10.1016\/j.berh.2020.101503_bib40","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.3899\/jrheum.091402","article-title":"Anticyclic citrullinated peptide antibodies as markers of erosive arthritis in antisynthetase syndrome","volume":"37","author":"Cavagna","year":"2010","journal-title":"J\u00a0Rheumatol"},{"issue":"20","key":"10.1016\/j.berh.2020.101503_bib41","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/MD.0000000000000523","article-title":"In antisynthetase syndrome, ACPA are associated with severe and erosive arthritis: an overlapping rheumatoid arthritis and antisynthetase syndrome","volume":"94","author":"Meyer","year":"2015","journal-title":"Medicine (Baltim)"},{"issue":"5","key":"10.1016\/j.berh.2020.101503_bib42","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s10067-019-04471-y","article-title":"Sonographic findings from inflammatory arthritis due to antisynthetase syndrome","volume":"38","author":"Miller","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2020.101503_bib43","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/rheumatology\/keu404","article-title":"Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients","volume":"54","author":"Lef\u00e8vre","year":"2015","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.berh.2020.101503_bib44","first-page":"139","article-title":"The journey of rheumatoid arthritis patients: a review of reported lag times from the onset of symptoms","volume":"9","author":"Barhamain","year":"2017","journal-title":"Open Access Rheumatol Res Rev"},{"key":"10.1016\/j.berh.2020.101503_bib45","article-title":"Anti-Jo-1 syndrome often misdiagnosed as rheumatoid arthritis (for many years): a single-center experience","author":"Kumar","year":"2019","journal-title":"J\u00a0Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"issue":"1","key":"10.1016\/j.berh.2020.101503_bib46","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2133.2006.07593.x","article-title":"\u201cMechanic's hands\u201d: a misleading cutaneous sign of the antisynthetase syndrome","volume":"156","author":"Bachmeyer","year":"2007","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2020.101503_bib47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.annder.2018.11.010","article-title":"Mechanics hands in patients with antisynthetase syndrome: 25 cases","volume":"146","author":"Gusdorf","year":"2019","journal-title":"Ann Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.berh.2020.101503_bib48","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s10067-017-3598-5","article-title":"\u201cHiker's feet\u201d: a novel cutaneous finding in the inflammatory myopathies","volume":"36","author":"Cox","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2020.101503_bib49","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.semarthrit.2016.03.011","article-title":"Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group","volume":"46","author":"Trallero-Aragu\u00e1s","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2020.101503_bib50","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/rheumatology\/keq430","article-title":"Association between nail-fold capillary findings and disease activity in dermatomyositis","volume":"50","author":"Mugii","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2020.101503_bib51","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.12688\/f1000research.20646.1","article-title":"Cutaneous manifestations of dermatomyositis characterized by myositis-specific autoantibodies","volume":"8","author":"Okiyama","year":"2019","journal-title":"F1000Research."},{"issue":"10","key":"10.1016\/j.berh.2020.101503_bib52","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/1346-8138.15049","article-title":"Clinical manifestations of skin, lung and muscle diseases in dermatomyositis positive for anti-aminoacyl tRNA synthetase antibodies","volume":"46","author":"Fukamatsu","year":"2019","journal-title":"J\u00a0Dermatol"},{"issue":"26","key":"10.1016\/j.berh.2020.101503_bib53","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1097\/MD.0000000000000798","article-title":"Myocarditis in patients with antisynthetase syndrome: prevalence, presentation, and outcomes","volume":"94","author":"Dieval","year":"2015","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.berh.2020.101503_bib54","author":"Alexis"},{"issue":"4","key":"10.1016\/j.berh.2020.101503_bib55","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.rdc.2011.09.007","article-title":"Paraneoplastic myalgias and myositis","volume":"37","author":"Aggarwal","year":"2011","journal-title":"Rheum Dis Clin N Am"},{"issue":"2","key":"10.1016\/j.berh.2020.101503_bib56","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10067-016-3453-0","article-title":"Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis","volume":"36","author":"Ceribelli","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2020.101503_bib57","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A\u00a0longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatol Oxf Engl"},{"issue":"8","key":"10.1016\/j.berh.2020.101503_bib58","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/RHU.0b013e31823b1878","article-title":"Antisynthetase syndrome and malignancy: our experience","volume":"17","author":"Casta\u00f1eda-Pomeda","year":"2011","journal-title":"J\u00a0Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"issue":"3","key":"10.1016\/j.berh.2020.101503_bib59","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.autrev.2018.10.004","article-title":"Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono- and multispecific immunoassays","volume":"18","author":"Damoiseaux","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.berh.2020.101503_bib60","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1007\/s00330-019-06152-5","article-title":"Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome","volume":"29","author":"Liu","year":"2019","journal-title":"Eur Radiol"},{"issue":"10","key":"10.1016\/j.berh.2020.101503_bib61","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","article-title":"Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.berh.2020.101503_bib62","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MD.0b013e318260977c","article-title":"Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature","volume":"91","author":"Labirua-Iturburu","year":"2012","journal-title":"Medicine (Baltim)"},{"issue":"6","key":"10.1016\/j.berh.2020.101503_bib63","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1378\/chest.08-2233","article-title":"Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature","volume":"135","author":"Kalluri","year":"2009","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.berh.2020.101503_bib64","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.autrev.2019.05.002","article-title":"Anti-OJ autoantibodies: rare or underdetected?","volume":"18","author":"Vulsteke","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.berh.2020.101503_bib65","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5858\/arpa.2013-0667-OA","article-title":"The pulmonary histopathology of anti-KS transfer RNA synthetase syndrome","volume":"139","author":"Schneider","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.berh.2020.101503_bib66","article-title":"The myositis clinical phenotype associated with anti-Zo autoantibodies: a case series of nine UK patients","author":"Tansley","year":"2019","journal-title":"Rheumatol Oxf Engl"},{"issue":"7","key":"10.1016\/j.berh.2020.101503_bib67","doi-asserted-by":"crossref","first-page":"909","DOI":"10.6061\/clinics\/2013(07)04","article-title":"Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis","volume":"68","author":"Cruellas","year":"2013","journal-title":"Clinics"},{"issue":"6","key":"10.1016\/j.berh.2020.101503_bib68","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","article-title":"Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody","volume":"41","author":"Marie","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2020.101503_bib69","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/08916930600623791","article-title":"In patients with antisynthetase syndrome the occurrence of anti-Ro\/SSA antibodies causes a more severe interstitial lung disease","volume":"39","author":"La Corte","year":"2006","journal-title":"Autoimmunity"},{"issue":"9","key":"10.1016\/j.berh.2020.101503_bib70","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00296-009-0884-9","article-title":"Characteristics of interstitial lung disease in SS-A positive\/Jo-1 positive inflammatory myopathy patients","volume":"29","author":"V\u00e1ncsa","year":"2009","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.berh.2020.101503_bib71","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11926-018-0731-7","article-title":"Management of interstitial lung disease in patients with myositis specific autoantibodies","volume":"20","author":"Mecoli","year":"2018","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.berh.2020.101503_bib72","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11926-012-0246-6","article-title":"Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment","volume":"14","author":"Mimori","year":"2012","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"10.1016\/j.berh.2020.101503_bib73","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/s10165-007-0553-3","article-title":"Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis\/polymyositis: a retrospective study","volume":"17","author":"Takada","year":"2007","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2020.101503_bib74","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10067-017-3854-8","article-title":"Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study","volume":"37","author":"Nakazawa","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2020.101503_bib75","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A\u00a0retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"Mira-Avendano","year":"2013","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.berh.2020.101503_bib76","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.chest.2019.05.023","article-title":"Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease","volume":"156","author":"Huapaya","year":"2019","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.berh.2020.101503_bib77","first-page":"436","article-title":"Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease","volume":"31","author":"Labirua-Iturburu","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2020.101503_bib78","series-title":"ACR meeting abstracts","article-title":"Calcineurin inhibitor for the treatment of myositis-associated interstitial lung disease: comparison between cyclosporine and tacrolimus","author":"Takahisa","year":"2018"},{"issue":"1","key":"10.1016\/j.berh.2020.101503_bib79","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10067-014-2803-z","article-title":"Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review","volume":"34","author":"Ge","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2020.101503_bib81","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatol Oxf Engl"},{"issue":"2","key":"10.1016\/j.berh.2020.101503_bib82","doi-asserted-by":"crossref","first-page":"e639","DOI":"10.1097\/MJT.0000000000000245","article-title":"Successful treatment of life-threatening interstitial lung disease secondary to antisynthetase syndrome using rituximab: a case report and review of the literature","volume":"23","author":"Dasa","year":"2016","journal-title":"Am J Therapeut"},{"issue":"8","key":"10.1016\/j.berh.2020.101503_bib83","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","article-title":"Rituximab treatment of the anti-synthetase syndrome: a retrospective case series","volume":"48","author":"Sem","year":"2009","journal-title":"Rheumatol Oxf Engl"},{"issue":"4","key":"10.1016\/j.berh.2020.101503_bib84","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.rmed.2012.01.001","article-title":"Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome","volume":"106","author":"Marie","year":"2012","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.berh.2020.101503_bib85","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3899\/jrheum.170541","article-title":"Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review","volume":"45","author":"Doyle","year":"2018","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2020.101503_bib86","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2020.101503_bib87","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rmed.2019.05.012","article-title":"Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease","volume":"154","author":"Huapaya","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.berh.2020.101503_bib89","article-title":"Pulmonary rehabilitation for interstitial lung disease","volume":"10","author":"Dowman","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.berh.2020.101503_bib90","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12890-017-0476-5","article-title":"Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: a multicenter prospective study","volume":"17","author":"Tonelli","year":"2017","journal-title":"BMC Pulm Med"},{"issue":"1","key":"10.1016\/j.berh.2020.101503_bib91","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12931-018-0884-y","article-title":"Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial","volume":"19","author":"Perez-Bogerd","year":"2018","journal-title":"Respir Res"},{"issue":"12","key":"10.1016\/j.berh.2020.101503_bib92","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023998","article-title":"Systematic review and meta-analysis of prognostic factors for idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"8","author":"Kamiya","year":"2018","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.berh.2020.101503_bib93","first-page":"858","article-title":"Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome","volume":"37","author":"Casal-Dominguez","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2020.101503_bib94","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","article-title":"Treatment in myositis","volume":"14","author":"Oddis","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2020.101503_bib95","series-title":"(Idiopathic inflammatory myopathy) - full text view - ClinicalTrials.gov [internet]","article-title":"Study evaluating efficacy and safety of ooctagam 10% in patients with dermatomyositis","year":"2016"},{"issue":"2","key":"10.1016\/j.berh.2020.101503_bib96","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2020.101503_bib97","doi-asserted-by":"crossref","DOI":"10.1186\/s12891-015-0710-3","article-title":"Biologic predictors of clinical improvement in rituximab-treated refractory myositis","volume":"16","author":"Reed","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"10.1016\/j.berh.2020.101503_bib98","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/joim.12481","article-title":"Physical exercise as a treatment for adult and juvenile myositis","volume":"280","author":"Alexanderson","year":"2016","journal-title":"J\u00a0Intern Med"},{"issue":"12","key":"10.1016\/j.berh.2020.101503_bib99","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","article-title":"A\u00a0high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies","volume":"67","author":"Dastmalchi","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2020.101503_bib100","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s10067-015-3023-x","article-title":"Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD)","volume":"34","author":"Rojas-Serrano","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2020.101503_bib101","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.berh.2020.101503_bib102","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/acr.21895","article-title":"Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome","volume":"65","author":"Marie","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"3","key":"10.1016\/j.berh.2020.101503_bib103","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3899\/jrheum.181141","article-title":"Evolution of pulmonary function in a cohort of patients with interstitial lung disease and positive for antisynthetase antibodies","volume":"47","author":"Gonz\u00e1lez-P\u00e9rez","year":"2019","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2020.101503_bib104","first-page":"874","article-title":"The pulmonary histopathologic manifestations of the anti-Jo-1 tRNA synthetase syndrome","volume":"23","author":"Yousem","year":"2010","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"issue":"3","key":"10.1016\/j.berh.2020.101503_bib105","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/thoraxjnl-2013-203843","article-title":"Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants","volume":"69","author":"Walsh","year":"2014","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.berh.2020.101503_bib106","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1513\/AnnalsATS.201807-443OC","article-title":"Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases","volume":"16","author":"Adegunsoye","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.berh.2020.101503_bib107","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.rmed.2017.04.007","article-title":"The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies","volume":"127","author":"Tanizawa","year":"2017","journal-title":"Respir Med"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694220300206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694220300206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:20:33Z","timestamp":1761499233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694220300206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1521694220300206"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2020.101503","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical manifestations and treatment of antisynthetase syndrome","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2020.101503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101503"}}